Sanofi ADS (SNY) Earnings Date & Reports

Key Takeaways

• Sanofi reported third-quarter 2026 net sales of €14,444 million, up 16.2% on a reported basis and 14.3% at constant exchange rates (CER, which strips out currency movements).
• Business earnings per share (EPS, a non-IFRS profit measure Sanofi uses to show operational performance) came in at €3.55, up 19.6% at CER and ahead of the roughly €2.79 analysts had expected.
• Dupixent, the company's flagship immunology medicine, grew 34.8% to about €5.7 billion, while sales of newer launched drugs climbed 31.4% to €1.4 billion.
• Vaccines were the main drag, falling 6.6% to €3.2 billion on expected timing shifts in respiratory-prevention products.
• Management raised its full-year 2026 outlook for a second time, now guiding to low-teens sales growth and mid-teens business EPS growth at CER.
• For additional context on Sanofi's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for a fuller view of the stock's latest developments.
• You can also discover momentum and signal-based ideas across the market by exploring Trending AI Robots.

Earnings Context and Why It Matters

Sanofi's third-quarter 2026 results arrived at a pivotal moment for the French pharmaceutical giant. Investors are closely watching how the company manages its dependence on Dupixent, which is now generating more than €5 billion in a single quarter, while preparing for that drug's eventual loss of exclusivity (LOE, when patent protection expires) early next decade. The quarter also tested Sanofi's ability to sustain cost discipline, broaden its newer product launches, and offset softer vaccine demand. With management signaling that mergers and acquisitions (M&A) will play a central role in reshaping the portfolio, this report offers a clear read on both near-term execution and the longer-term strategy to protect earnings growth.

Reported Results

Sanofi delivered third-quarter 2026 net sales of €14,444 million, a 16.2% increase on a reported basis and 14.3% at CER, topping the roughly €13.6 billion analysts had projected. Business EPS reached €3.55, up 19.6% at CER and 22.0% at actual exchange rates, comfortably above consensus estimates near €2.79. IFRS net income (calculated under International Financial Reporting Standards) rose 7.8% to €3,021 million, with IFRS EPS of €2.52.

Growth was led by Dupixent, which climbed 34.8% to about €5.7 billion, and by pharma launches, up 31.4% to €1.4 billion on contributions from ALTUVIIIO, Ayvakit, and Rezurock. Vaccines declined 6.6% to €3.2 billion, reflecting anticipated phasing in respiratory prevention. Research and development (R&D) expenses were broadly stable at €1.8 billion, while selling and general expenses fell 0.9% to €2.3 billion, underscoring cost discipline. Free cash flow rose 9.2% to €3,269 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Sanofi, it can serve as a complementary way to identify comparable setups across the healthcare and pharmaceutical space.

Market Reaction and Investor Sentiment

The market's initial read on Sanofi's report was broadly constructive, with the results exceeding both revenue and earnings expectations and management upgrading its 2026 guidance. Sentiment heading into the print had been shaped by concerns about Dupixent's concentration risk and softness in the vaccines segment. The better-than-expected Dupixent growth and the second guidance raise helped address those worries, while the confirmed vaccine decline remained a notable offset. Investors also weighed the expanded alliance with Regeneron in immunology and the portfolio-simplification partnership with Cheplapharm as signals that management is actively repositioning the business ahead of Dupixent's loss of exclusivity.

Forward Outlook and Key Factors to Monitor

Following the upgrade, Sanofi now expects full-year 2026 sales to grow in the low-teens percentage range at CER and business EPS to grow in the mid-teens percentage range at CER. That guidance signals management's confidence in sustaining momentum through the remainder of the year, supported by Dupixent and the newer pharma launches.

Looking further ahead, investors will want to monitor the trajectory of Dupixent as it approaches loss of exclusivity, the pace of growth from recently launched medicines, and whether vaccine sales stabilize once the respiratory-prevention phasing normalizes. Cost trends will also matter, given the role of expense discipline in driving the strong business EPS growth.

Management has flagged business development and M&A as critical tools for reshaping the portfolio, so deal activity in immunology and other therapeutic areas is likely to draw attention. Pipeline progress, including regulatory approvals and submissions, will remain another key catalyst as Sanofi works to protect earnings growth into the next decade.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations